1. Buntz B. Top Pharma Companies Ranked by 2023 R&D Spend. Drug Discovery and Development, 30.04.2024. Available at: https://www.drugdiscoverytrends.com/top-pharma-companies-2023-rd-spend (accessed 20.03.2025).

2. Chandra A., Drum J., Daly M., Misberger H., Spare S., Neumann U., Martin S., Kirson N. Comprehensive Measurement of Biopharmaceutical R&D Investment. Nature Reviews Drug Discovery, 2024, vol. 23, pp. 652-653. Available at: http://doi.org/10.1038/d41573-024-00131-2

3. Yeung A.W.K., Atanasov A.G., Sheridan H., Klager E., Eibensteiner F., Volkl-Kernsock S., Kletecka-Pulker M., Willschke H., Schaden E. Open Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis. Frontiers in Pharmacology, 2021, vol. 11, art. 587526. Available at: https://doi.org/10.3389/fphar.2020.587526

4. Chesbrough H.W. Open Innovation: The New Imperative for Creating and Profiting from Technology. Boston, Harvard Business Press, 2003. 227 p.

5. Teece D. Business Models, Business Strategy and Innovation. Long Range Planning, 2010, vol. 43, iss. 2-3, pp. 172-194. Available at: https://doi.org/10.1016/j.lrp.2009.07.003

6. Foss N.J., Saebi T. Fifteen Years of Research on Business Model Innovation: How Far Have We Come, and Where Should We Go? Journal of Management, 2017, vol. 43, iss. 1, pp. 200-227. Available at: https://doi.org/10.1177/0149206316675927

7. Li J.J. Blockbuster Drugs: The Rise and Fall of the Pharmaceutical Industry. Oxford, Oxford University Press, 2014. 223 p.

8. Coghlan A. Blockbuster challenge. New Scientist, 12.06.2004. Available at: https://www.newscientist.com/article/mg18224515-800-blockbuster-challenge/ (accessed 20.03.2025).

9. Bingham A. Whither Pharma? The Demise of Pharma’s Blockbuster Business Model. Drug Discovery World (DDW), 06.08.2006. Available at: https://www.ddw-online.com/whither-pharma-the-demise-of-pharmas-blockbusterbusiness-model-723-200608/ (accessed 24.03.2025).

10. Collier R. Bye, Bye Blockbusters, Hello Niche Busters. Canadian Medical Association Journal, 2011, vol. 183, no. 11, pp. E697-E698. Available at: https://doi.org/10.1503/cmaj.109-3874

11. Cockburn I.M. Is Pharmaceutical Industry in a Productivity Crisis? Jaffe A.B., Lerner J., Stern S., eds. Innovation Policy and Economy. Cambridge, MIT Press, 2006, vol. 7, pp. 1-32. Available at: https://doi.org/10.1086/ipe.7.25056188

12. Laermann-Nguen U., Backfisch M. Innovation Crisis in the Pharmaceutical Industry? A Survey. SN Business & Economics, 2021, vol. 1, no. 12, art. 164. Available at: https://doi.org/10.1007/s43546-021-00163-5

13. DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of Innovation in the Pharmaceutical Industry. Journal of Health Economics, 1991, vol. 10, iss. 2, pp. 107-142. Available at: https://doi.org/10.1016/0167-6296(91)90001-4

14. DiMasi J.A., Hansen R.W., Grabowski H.G. The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics, 2003, vol. 22, iss. 2, pp. 151-185. Available at: https://doi.org/10.1016/s0167-6296(02)00126-1

15. Gilbert J., Henske P., Singh A. Rebuilding Big Pharma’s Business Model. In Vivo: The Business & Medicine Report, 2003, vol. 21, no. 10, pp. 1-10. Available at: http://plg-group.com/wp-content/uploads/2014/03/Rebuilding-big-pharmas-business-model-Jim-Gilbert-Windhove.pdf (accessed 24.03.2025).

16. DeRuiter J., Holton P.L. Drug Patent Expirations and the “Patent Cliff”. U.S. Pharmacist, 2012, vol. 37 (6), pp. 12-20. Available at: https://www.uspharmacist.com/article/drug-patent-expirations-and-the-patent-cliff (accessed 24.03.2025).

17. Gibney M. The ‘Innovation Gap’ Haunts Big Pharma, and the Race Is on for the Next Blockbusters. PharmaVoice, 28.04.2022. Available at: https://www.pharmavoice.com/news/innovation-gap-pharma-blockbuster-drugbiotech/622804/ (accessed 25.03.2025).

18. Schuhmacher A., Hinder M., Dodel A., Gassmann O., Hartl D. Investigating the Origins of Recent Pharmaceutical Innovation. Nature Reviews Drug Discovery, 2023, vol. 22, pp. 781-782. Available at: https://doi.org/10.1038/d41573-023-00102-z 

19. Van de Vyver B., Berghauser Pont L., Parekh R., Smietana K., Robke L. External Innovation: Biopharma Dealmaking to Boost R&D Productivity. McKinsey Quarterly, 09.01.2025. Available at: https://www.mckinsey.com/industries/life-sciences/our-insights/external-innovation-biopharma-dealmaking-to-boost-r-and-d-productivity (accessed 15.03.2025).

20. Iazzolino G., Bozzo R. Partnership Models for R&D in the Pharmaceutical Industry. Canci J.K., Mekler P., Mu G., eds. Quantitative Models in Life Science Business. Springer, Cham., 2023, pp. 29-48. Available at: https://doi.org/10.1007/978-3-031-11814-2_3

21. Gautam A., Pan Xiaogang. The Changing Model of Big Pharma: Impact of Key Trends. Drug Discovery Today, 2016, vol. 21, iss. 3, pp. 379-384. Available at: https://doi.org/10.1016/j.drudis.2015.10.002

22. Bowman M.L., Sousa J.J.S., Pina M.E.T. Regulatory Issues for Orphan Medicines: A Review. Health Policy and Technology, 2020, vol. 9, iss. 1, pp. 115-121. Available at: https://doi.org/10.1016/j.hlpt.2019.11.008

23. Niu S., Happe L.E., Abuloha S., Svensson M. Concentration of Spending and Share of Specialty Drug Spending in Medicare Part D over a 10-Year Period. Journal of Managed Care & Specialty Pharmacy, 2024, vol. 30, no. 12, pp. 1355-1363. Available at: https://doi.org/10.18553/jmcp.2024.30.12.1355

24. Niazi S.K., Mariam Z. Computer-aided Drug Design and Drug Discovery: A Prospective Analysis. Pharmaceuticals, 2024, vol. 17, no. 1, pp. 1-22. Available at: https://doi.org/10.3390/ph17010022

25. Kint S., Dolfsma W., Robinson D. Strategic Partnerships for AI-driven Drug Discovery: The Role of Relational Dynamics. Drug Discovery Today, 2024, vol. 29, iss. 12, art. 104242. Available at: https://doi.org/10.1016/j.drudis.2024.104242

26. Schuhmacher A., Gassman O., Bieniok D., Hinder M., Hartl D. Open Innovation: A Paradigm Shift in Pharma R&D? Drug Discovery Today, 2022, vol. 27, iss. 9, pp. 2395-2405. Available at: https://doi.org/10.1016/j.drudis.2022.05.018

1. The Pharmaceutical Industry and Global Health: Facts and Figures 2022. Geneva, The International Federation of Pharmaceutical Manufacturers & Associations, 20.09.2022. Available at: https://www.ifpma.org/publications/facts-and-figures-2022-the-pharmaceutical-industry-and-global-health/ (accessed 24.01.2025).

2. 2002 Drug Industry Profits: Hefty Pharmaceutical Company Margins Dwarf Other Industries. Washington, Public Citizen’s Congress Watch, June 2003. 13 p. Available at: https://www.citizen.org/wp-content/uploads/pharma_report.pdf (accessed 20.12.2024).

3. FDA New-Medication Approval Times Dropped Significantly in Recent Years. U.S. Pharmacist, 22.01.2020. Available at: https://www.uspharmacist.com/article/fda-newmedication-approval-times-dropped-significantly-in-recent-years (accessed 24.03.2025).

4. Blockbuster Product Patent Expiry. Journal of Generic Medicines, 2004, vol. 1, iss. 3, pp. 273-280. Available at: https://doi.org/10.1057/palgrave.jgm.4940032

5. From Vision to Decision: Pharma 2020. New York, PWC, 2012. 53 p. Available at: https://www.pwc.com/jp/ja/japan-knowledge/archive/assets/pdf/pharma-2020-vision-to-decision.pdf (accessed 25.03.2025).

6. Externalizing Pharma Innovation Is the Winning Strategy – Now More Than Ever. New York, EY, 2019. Available at: https://www.ey.com/en_gl/industries/life-sciences (accessed 21.12.2024).

7. Insights into the 2023 U.S. Pharmaceutical Market. IQVIA, 25.07.2023. Available at: https://www.iqvia.com/locations/united-states/blogs/2023/07/insights-into-the-2023-us-pharmaceutical-market (accessed 21.12.2024).

8. AI in Pharmaceuticals Promises Innovation, Speed, and Savings. SP Global, 01.10.2024. Available at: https://www.spglobal.com/ratings/en/research/articles/241001-ai-in-pharmaceuticals-promises-innovation-speed-and-savings-13254002 (accessed 20.12.2024).